The enhancer of zeste homolog 2 (EZH2) and its highly related homolog EZH1 are considered to be epigenetic silencing factors, and they play key roles in the growth and differentiation of cells as the core components of polycomb repressive complex 2 (PRC2). EZH1 and EZH2 are known to have a role in human malignancies, and alterations in these two genes have been implicated in transformation of human malignancies. Inhibition of EZH1/2 has been shown to result in tumor regression in humans and has been studied and evaluated in the preclinical setting and in multiple clinical trials at various levels. Our work thus contributes to the understanding of the relationship between regulatory molecules associated with EZH1/2 proteins and tumor progression, and may provide new insights for mechanism-based EZH1/2-targeted therapy in tumors.

zeste 同源物 2 (EZH2) 的增强子及其高度相关的同源物 EZH1 被认为是表观遗传沉默因子，它们作为多梳抑制复合物 2 (PRC2) 的核心成分，在细胞的生长和分化中发挥着关键作用。已知 EZH1 和 EZH2 在人类恶性肿瘤中起作用，并且这两个基因的改变与人类恶性肿瘤的转化有关。已显示抑制 EZH1/2 可导致人类肿瘤消退，并已在临床前环境和多个不同水平的临床试验中进行研究和评估。因此，我们的工作有助于理解与 EZH1/2 蛋白相关的调节分子与肿瘤进展之间的关系，并可能为基于机制的 EZH1/2 肿瘤靶向治疗提供新见解。